Omiloxetine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Omiloxetine
Omiloxetine.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C27H25F2NO4
Molar mass 465.489 g/mol
3D model (JSmol)
Density 1.3±0.1 g/cm3
Melting point 228.65 °C (443.57 °F)
Boiling point 587.2 °C (1,089.0 °F)
Solubility in water 0.0015 mg/mL (20 °C)

Omiloxetine (omiloextinum, omiloxetino INN)[1]:212-213 was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2][3]

References[edit]

  1. ^ WHO Drug Information, Vol. 10, No. 4, 1996 Proposed INN: List 76
  2. ^ Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Retrieved 2012-05-19. 
  3. ^ De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Retrieved 2012-05-19.